Tech Company CollectionsBiotechnology Companies

Tenvie Therapeutics is a biotechnology company founded to improve patients' lives with neurological, cardiometabolic, and ophthalmic diseases. The company is focused on developing small molecules targeting brain inflammation, metabolic dysfunction, and lysosomal issues, with a robust pipeline inherited from Denali Therapeutics. Tenvie is progressing a range of therapeutics aimed at addressing neurological, cardiometabolic, and ophthalmic conditions. Its collection of fully owned, highly brain-penetrant, and precisely designed peripherally restricted small molecules targets three main factors of disease: alleviating inflammation, correcting metabolic dysfunction, and rejuvenating lysosomal function.

Ouroboros Medicines is a biotechnology company that specializes in immunology and focuses on treating long-term immune-mediated illnesses. The company addresses chronic immune-mediated conditions directly by integrating scientific knowledge, a proven history of progressing cell-depleting treatments through clinical trials, and a strong pipeline.

Helicore Biopharma is at the forefront of developing cutting-edge treatments for obesity and related disorders.

Cradle is a cryonics company that develops and proves the feasibility of human organs and whole-body reversible cryopreservation. That aims to focus on pausing and restarting biological functions through freezing to prevent tissue damage in dead bodies.

Ambrosia Biosciences offers drug development services for small molecule-based therapies for obesity and other metabolic disorders.

Nura Health is a molecular diagnostics company whose mission is to advance women's health through the development and delivery of novel practice-changing non-invasive tests. We prioritize innovative, evidence-based diagnostic methods enhanced by AI & Machine Learning in order to improve clinical outcomes for complex and debilitating diseases such as endometriosis, infertility disorders, and genetic conditions that impact quality of life and longevity.

Kailera Therapeutics is a clinical-stage biotechnology company that provides revolutionary therapies for treating obesity and related diseases.

Seaport Therapeutics operates as a clinical stage biopharmaceutical company.

Bambusa Therapeutics operates as biotechnology company, that focuses on developing bispecific antibodies.

Chai Discovery creates Chai-1, a multi-modal foundation model designed for predicting molecular structures relevant to drug discovery. The model facilitates the unified prediction of proteins, small molecules, and nucleic acids, and is available for free for commercial applications. By enabling accurate predictions without the need for multiple sequence alignments, Chai-1 advances the capabilities of molecular modeling in the life sciences.

KALM Therapeutics provides non-steroidical treatment for eczema and psoriasis.

K-Scale Labs is a robotic engineering company specializing in creating open-source humanoid robots.

Jupiter Endovascular is a medical technology start-up. Its mission is to cover the entire spectrum of cardiovascular illness, seeing compelling potential to reinvent treatments for millions of people.

Kivu Bioscience is a biotech company developing next-generation antibody-drug conjugates to deliver best-in-class therapeutics and focused on rapidly advancing next generation transformative assets.

Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intelligence to learn the language of life and transform how we treat disease. The company seeks to rethink the drug discovery and development process from end-to-end by bringing together leading talent across three core areas: machine learning research to better understand biology, expansive data generation to power new models, and robust therapeutic product development to treat disease. Xaira is headquartered in the San Francisco Bay Area.

Trace Neuroscience is a biopharmaceutical company that aims to extend the promise of genetic medicine to patients with neurodegenerative illnesses.

DeltaGen is an enterprise AI company transforming buyside M&A by automating 80% of manual workflows—eliminating inefficiencies and accelerating deal velocity for corporate development teams, private equity firms, and strategic acquirers. Unlike traditional AI tools that rely on manual prompting, DeltaGen’s no-prompt AI delivers highly accurate, deterministic insights with seamless integration.

Jade Biosciences is developing transformative therapies to redefine the standard of care for inflammation and immunology indications.

Eyconis, Inc. is a privately held, pre-clinical stage biopharmaceutical company focused on transforming the ophthalmology treatment paradigm through the development, manufacture, and commercialization of novel, best-in-class therapeutics for eye diseases. The Company is advancing a pipeline of therapeutic candidates addressing areas of high unmet need including wet age-related macular degeneration (AMD). Eyconis is partnered with a syndicate of leading biopharma investors including Frazier Life Sciences, RA Capital Management, venBio Partners, and HealthQuest Capital. The Company is headquartered in Redwood City, California, including research & development laboratories with scientific and manufacturing team members.

GondolaBio is a clinical-stage biopharmaceutical company focused on developing next-generation therapeutics for genetic diseases. Originally launched as BridgeBioX, a subsidiary of BridgeBio, GondolaBio secured $300M in private financing from external investors in 2024 and became an independent company within the BridgeBio ecosystem. The company aims to leverage cutting-edge biological research to create breakthrough medicines addressing high unmet needs across multiple therapeutic areas, including neurology, pulmonology, cardiology, nephrology, and endocrinology. Located on the Stanford Life Sciences campus, GondolaBio fosters a unique hybrid environment where top scientists from around the world collaborate with senior leadership and advisors, blending industry expertise with academic innovation.

Alys Pharmaceuticals engages in immuno-dermatology services. The company is reshaping the treatment landscape through advanced scientific innovations and a strong research and development-focused multi-platform pipeline. Alys emerged as a result of the strategic aggregation of 6 asset-centric companies backed by Medicxi.

Timberlyne Therapeutics is a clinical-stage biopharmaceutical company that develops and commercializes revolutionary medicines for autoimmune illnesses. The company utilizes its team's experience in drug development to secure top-tier assets focused on promising targets, and implementing them in disease areas with considerable unmet needs.

VisiRose offers an innovative approach to treating infectious keratitis and other eye diseases.

Newleos Therapeutics is a biotech startup dedicated to producing safer and more effective neuroscience medicines.

Coeptis Therapeutics focuses on the development and acquisition of pharmaceutical products. Coeptis’ pipeline is evolving from the partnerships being created with multiple pharmaceutical companies currently. As these relationships unfold, the product pipeline will be updated accordingly.

Noded Ai is preparing yourself for that customer meeting is tough. Noded brings them all together using your notes history and gives you exactly what you needed , when you need it. So you’re always prepared and one step ahead.

GEMMABio is a therapeutics company that supports the rare disease community.

Mirador Therapeutics envisions precision medicine for immune-mediated inflammatory and fibrotic diseases.

Navigator Medicines operate as a biotech company that leads the advancement of biologics for targeted immune regulation & restoration.

Converge Bio is at the forefront of integrating Generative AI with biological data. Our mission is to empower biotech and pharmaceutical companies to discover and develop more effective drugs faster, utilizing the power of Large Language Models (LLMs) specifically trained on biological languages.

Developing innovative therapeutics to materially improve the lives of patients. We strive to be transparent and open in our goals, plans, and progress.

nChroma Bio's integrated product engine allows for safe, accurate, and targeted in vivo administration, addressing major shortcomings of current genetic medicine techniques.

Kardigan is a patient-driven heart health firm that is revolutionizing cardiovascular drug development to produce medicines that take patients from symptom management to functional cures.

Peregrine Health is a healthcare company formed by Integrative Life Network (ILN) and Integrative Health Centers.

Primrose Bio is a biotech company that focuses on discovery, development, and manufacturing of new molecules. innovative therapeutics, vaccines and ingredients to aevance global health.

Speeding lifesaving cures with AI-driven design & real-time insights for faster, intuitive clinical development & patient access.

Taxa is a synthetic microbiome company sculpting the skin microbiome using genetic engineering technologies such as CRISPR/spCas9.

Kincell Bio collaborates with cell therapy developers by using considerable scientific experience and industry understanding. Transparency, accountability, and accuracy are essential to what makes us a reliable partner for process and analytical development, CMC assistance, and high-quality clinical cell therapy manufacturing services.

TwoStep Therapeutics is developing novel tumor-targeting therapeutics for solid tumors.

Predicta Biosciences is a precision oncology firm that integrates multiomics and liquid biopsies to create diagnostic tools and therapies. They also have an in-house pipeline for novel immunotherapy targets in pre-clinical stages.

EvolutionaryScale is a developer of biological artificial intelligence models for therapeutic design. The business predicts protein structures by combining biological data from DNA sequences, gene expression, and epigenetic states, allowing scientists to use massive language models to create RNA-based medicinal therapies.

Biostate AI develops generative AI that benefit all human health.

Sealonix focuses on the development and commercialization of hemostatic sealants using its proprietary biomaterials. Sealonix is working on a sealant patch that will provide quick hemostasis for abdominopelvic and orthopedic operations. The PramStat patch is intended to bioabsorb within one week of implantation.

NeuroBionics is pioneering the future of precision bioelectronic medicine by inventing the next generation of implanted devices that will seamlessly interface with the human body.

Avenue Biosciences is pioneering the future of biotechnology, with a mission to transform the development of protein biologics for healthcare advancements. Our cutting-edge, high-throughput engineering platform transforms the production of protein biologics by enabling the simultaneous optimization of critical elements. This breakthrough technology enhances production efficiency, accelerates development timelines, and tackles the challenges of producing complex proteins. Our goal is to drive significant progress in the pharmaceutical industry by providing turnkey solutions that streamline production, improve quality, and unlock new therapeutic possibilities. Backed by validated proof of concept and compelling data, Avenue Biosciences is on a journey to transform healthcare and push the boundaries of what’s possible in protein biologics. We're a team of brilliant minds, each an expert in their field, united by a shared mission to make a real impact in a novel area of biotechnology. We are a highly experienced, entrepreneurial minded team with an impressive scientific background, that lives and breathes a casual, committed, and positive culture and spirit. A closer look We revolutionize protein production with our groundbreaking high-throughput engineering platform. This innovative technology significantly enhances overall production efficiency and quality. We optimize the production of natural single-chain proteins, monoclonal antibodies, bispecific antibodies, fusion proteins, mRNA therapies, and vaccines. Additionally, our platform accelerates the drug and vaccine discovery process. Our mission is to accelerate the development of protein expression systems, covering new protein therapeutics, biosimilars, and other protein expression systems within the biotechnology industry. Our engineering platform empowers biotechnology and pharmaceutical industry customers to speed up development timelines and facilitate the production of difficult-to-express proteins.

Founded in 2023 by a team of internationally recognized healthcare leaders, GalenusRx is revolutionizing medication safety with the power of precision. The company’s proprietary platform, APPRAISE, analyzes drug-drug, multi-drug, drug-gene, and drug-disease interactions to provide a unique and comprehensive risk assessment, individualized down to the DNA. Through the Lifesaving InsightsTM consulting service, Precision Clinical Pharmacists deliver tailored recommendations for safer, more effective drug regimens. Together, these solutions directly address polypharmacy and the potential for adverse drug events - a leading cause of death in the United States. GalenusRx’s deep data analysis also enhances the quality, safety, and efficiency of virtual clinical trials, allowing for biosimulations based on real patient data that don’t expose patients to risk. The benefits span from consumers to healthcare providers, insurers, and pharmaceutical companies, with GalenusRx’s technology leading the way toward better health outcomes and lower medical costs.

We know that drug development is both an art and a science. The work we do is incredibly technical, intentional, and specific, but there is an art to it - because we must leave room for creativity, innovation and spontaneity. Murals are paintings that transform overlooked or unused spaces - creating something impactful and meaningful. There remains many overlooked opportunities in cancer drug development. This is what inspires us. Our mission is simple, to create novel immunotherapies that can change patients’ lives so they can get back to what matters most - living. Mural Oncology is leveraging its industry-leading protein engineering platform to revolutionize cytokine-based immunotherapies for the treatment of cancer. Immunotherapies have been transformative for some people living with cancer, but unfortunately many patients still do not benefit - either because they are ineligible for treatment or they do not respond well to current therapies. We leverage our expertise in cytokine biology, immune cell modulation and our protein engineering capabilities to develop first and novel immunotherapies. Our goal is to deliver meaningful, clinical benefit across a wide range of cancers, including tumor types where immunotherapies have previously not been effective. Mural Oncology is developing a portfolio of programs to broaden the potential and reach of cytokine-based immunotherapies for the treatment of cancers. (NASDAQ: MURA)

Attovia Therapeutics is a biotherapeutics pipeline developer focused on immune-mediated illness and oncology. The company uses the nanobody platform to create tiny format binders with low picomolar affinity, increased selectivity, quicker internalization, and rapid tissue penetration, thereby assisting cancer patients' treatment.

Retension Pharmaceuticals is developing RTN-001, a differentiated, tissue-targeted PDE5 inhibitor that has been optimized for the treatment of uncontrolled hypertension. RTN-001 has been evaluated in over 265 subjects across 9 clinical trials. In these studies, RTN-001 was well tolerated and demonstrated a sustained and clinically significant impact on central and brachial blood pressure in patients with uncontrolled hypertension. RTN-001 is a second generation PDE5i that preferentially distributes to cardiovascular tissues, where it acts to mediate a sustained and clinically significant impact on central and brachial blood pressure in patients with uncontrolled hypertension.

Spyre Therapeutics combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for inflammatory bowel disease.

Shinobi Therapeutics focuses on creating hypoimmune CD8αβ iPS-T cells that work with the immune system to treat cancer and other diseases. The company utilizes advanced immune evasion technology to enhance the effectiveness and accessibility of cell therapies. Shinobi's innovative approach aims to reduce costs and improve patient outcomes through durable responses and redosing capabilities.

Atommap is a physics-based and ML-augmented computational drug discovery platform

Caladan Bio specializes in next-generation bioreactors, offering modular, affordable, and cutting-edge solutions.

Brightstar Therapeutics is a biotechnology company focused on innovative treatment options that improve clinical outcomes and quality of life for people living with corneal and ocular surface diseases.

Pi Health is a provider of platforms to assist oncology-related clinical trials with identifying sites and helping sponsors manage sites

Valora Therapeutics is a biotechnology company that provides engineering of chimeric antibodies .

Crop Diagnostix is a biotechnology company that uses RNA sequencing and AI for predictive agriculture.

We are Montara Therapeutics, a San Francisco-based precision-medicine neuroscience biotech startup. Our team boasts significant experience from successful biotech firms such as Mitokinin, Denali, and Soteria, supported by a world-class Scientific Advisory Board (SAB). We bring a new approach to tackling challenging established targets, along with unique experience in developing enzyme activators and domain expertise in mitophagy. Our mission is to create innovative therapies for diseases of the CNS, with a focus on precision medicine and genetically validated targets to enhance drug safety and efficacy.

ParcelBio is a company that creating a programmable method for safely and precisely delivering mRNA to many cell types in the body.

Nanograb is a computational drug discovery company that uses AI to generate the best combination of binders to treat different diseases.

Edgewood Oncology is a clinical-stage biotechnology business established to fulfill the potential of BTX-A51 for patients with solid tumors that are genetically specified and hematologic malignancies. Our goal is to create a novel treatment that will prolong and enhance the lives of those with the greatest unmet medical needs.

Eris Biotech is a biotech company that developing hypoxia-activated prodrugs (HAPs) for the treatment of solid tumors.

CrossBridge Bio operates as a biotechnology company, innovates ADC therapeutics through stable dual linker payload technology.

Olio Labs utilizes AI for combo therapeutics, optimizing and minimizing side effects through automated discovery of protein interactions.

Amplifyer Bio is a biotechnology research company that develops technology of transformative potential for the liquid biopsy field.

Biogenesis is building the end-to-end platform for clinical research.

Vector Biomed is a state-of-the-art custom vector design and GMP manufacturing company. It is a source for safe, high-quality, reliably-manufactured Lentiviral vectors that are critical for producing gene medicines like CAR-T cell therapies and Stem Cell gene therapies.

Doron Therapeutics is a clinical-stage biotechnology company that has developed intra-articular biologic drugs derived from placental tissue and consistently delivers a host of beneficial growth factors with potent anti-inflammatory, tissue-protective, and regenerative capabilities pivotal to the progressive and degenerative disease of osteoarthritis.

Granza Bio is a company that developing cancer therapies based on human body's immune system.

Tern Therapeutics develops transformative, one-time genetic treatments for rare diseases.

SynsoryBio is a biotechnology research company that offers next-generation protein therapeutics services.

Advanced Medicine Partners is a biotechnology company that specializes in viral vector manufacturing for genes and cells.

DANNCE is a deep learning solution to automate behavioral analysis for drug development and disease diagnosis​. Our platform takes patient video as input and uses our proprietary 3-D pose tracking and behavioral analysis algorithms to quantify behavior. DANNCE will help clinicians see the unseeable and drug developers generate real world evidence by using movement data and computer vision.

Avenacy is a rapidly growing U.S.-based specialty pharmaceutical company focused on providing critical injectable medications used to treat patients in various medically supervised settings, from acute care hospitals to outpatient clinics and physician offices. Through a rigorous and optimized selection process, the Company is building out a pipeline of high-quality FDA approved injectable products to ensure a resilient portfolio that can meet the needs of today’s dynamic drug supply chain. With an experienced team, commitment to quality and reliability, and product offerings intended to facilitate safe and efficient patient care, Avenacy strives to be a trusted partner for essential injectable medications.

Mach5 Therapeutics is a biotechnology company.

Silo Pharma, Inc. is a developmental stage biopharmaceutical company. The Company specializes in developing novel therapeutics that address underserved conditions including PTSD, stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. Silo Pharma operates in the United States.

Infinity Bio is a Circulating Antibody Repertoire Profiling service company, leveraging a novel technology, MIPSA (Molecular Indexing of Proteins (or Peptides) by Self Assembly) developed by Dr. H. Ben Larman, a pioneer in this field. Our various antigen libraries provide cost effective, comprehensive and quantitative analyses of antibody responses to infections, vaccinations, self-antigens and allergens. Our proprietary method allows for the rapid and flexible content customization. Infinity Bio can design and create customer specific peptide libraries against any target of choice.

About HAPPY POTATO - Perfect Fries ! The world's best Flavored French Fries ! Feel the Flavor with everyone's favorite French fries Products Flavoring Perfect Fries

Junevity is a biotech rewinding complex metabolic disease. Based on 6 years of breakthrough research at UCSF, Junevity's REWIND platform identifies high-level regulators of metabolic disease with known pharmacological pathways. Junevity is advancing multiple therapeutic programs towards a new era of medicines.

Velorum Therapeutics produces powerful cancer treatments that starve tumors.

Long Description: Aiolos Bio is a biotech company focused on developing therapies for respiratory diseases like asthma as well as other immune conditions. The company is initially focused on advancing AIO-001, a monoclonal antibody therapy for moderate-to-severe asthma that only requires dosing every 6 months. Aiolos Bio was founded by an accomplished team with decades of drug development experience and leadership in the biotech industry.

Ti sento means “I hear you" in Italian. At Tisento Therapeutics, we believe that meaningful innovation requires understanding the problem, and that starts with listening. First and foremost, we listen to those impacted by debilitating diseases to understand the daily challenges they face. We also listen to healthcare providers, patient advocates, regulatory agencies, and scientific data. All these inputs inform our thinking and shape how we conduct our research, design our trials, and evolve our company. We are on a mission to deliver medicines that address what matters most. Our lead candidate is zagociguat (formerly CY6463), a Phase 2, first-in-class, brain-penetrant sGC stimulator, which is advancing in MELAS and other genetic mitochondrial diseases. Zagociguat is ideally suited to treat mitochondrial diseases with both CNS and peripheral symptoms, such as cognitive impairment, fatigue, and muscle weakness.

Pranax is a software company currently based in Pinehurst, Texas, United States. It has been founded in 2023.

RyboDyn, Inc. is targeting the dark proteome to make new immunotherapies. We are unlocking and validating previously undiscovered, disease-specific targets that will impact the treatment of cancer and autoimmune diseases by driving a new wave of targeted therapeutics. Our "targets-to-assets" therapeutics development program is supported by a scalable, in-house platform for lead discovery and optimization. We aim to deliver first-in-class assets that recognize these targets for treating solid tumors and diseases lacking effective treatment options.

AI-driven engineering of the proteome via RNA splicing control

Guardian Bio is centred on developing a personalised cell therapy based on dendritic cells.

LTZ develops novel immunotherapies to treat patients that suffer from cancer and other diseases with an unmet clinical need.

Founded by Flagship Pioneering, Empress re-imagines the process of small molecule drug discovery. Our bioplatform harnesses the power of evolution, human molecular and genetic data, and artificial intelligence to focus on endogenous sources of inherently drug-like small molecules as a uniquely quali... Read more

Enumera Molecular is a life science tools company developing rapid, low cost solutions for the of assessment of biomolecules via liquid biopsy.

Visiox is a privately funded biopharmaceutical company focused on the development and commercialization of ophthalmic therapeutic candidates to address highly prevalent diseases in need of new treatment options.

Developing extended-release PLG drug formulations takes $10M+ and 5-10 years. We enable drug manufacturers and CROs to shorten formulation discovery time by 30-50% by utilizing our automation and machine learning platform.

Stellaromics is a biotechnology company that specializes in 3D in situ multi-omic analysis technology.

DEM Bio is pioneering the next generation of immunotherapeutics that unleash macrophages and immune phagocytes to eliminate tumors by targeting ‘Don’t eat me’ (DEM) and ‘Eat me’ (EM) signals on cancer cells and macrophages. Founded by Longwood Fund and is supported by a syndicate of biotech investors and headquartered in Boston, MA.

CorriXR Therapeutics is a biotechnology company. The company is headquartered in Wilmington, Delaware, United States.

Integrated Biosciences, Inc. is a biotechnology company. The Company combines synthetic biology and machine learning to develop next-generation therapeutics for age-related diseases. Integrated Biosciences operates in the United States.

Ryne Biotechnology focuses on developing therapies for neurodegenerative movement disorders. The company was founded in 2022 and is headquartered in Cambridge, Massachusetts, United States.

Wild Microbes is a next-generation microbial platform that makes everything from plastics to proteins. They develop new microbial strains, making scaling sustainable products faster and cheaper than ever.

Izote Biosciences is a software company currently based in Berkeley, California, United States. It has been founded in 2022 by Victor Reyes-Umana.

Piezo Therapeutics develops a uniquely engineered platform that uses electric pulses and microneedles to deliver therapeutics to the body. The company was founded in 2022 and is headquartered in Atlanta, Georgia, United States.

Noetik is an AI-native biotechnology company. Noetik leverages in advanced machine learning methods to discover and develop cancer immunotherapies.